September 14, 2018

Valens Research Weekly Equity Idea Highlight for September 12, 2018 – Gilead Sciences, Inc.

This week the Valens Research team highlights our most interesting equity insight from across our tools and our analysis.

Management’s success in operating their core business, intelligent acquisitions to drive growth, low market expectations and growing management confidence in their outlook are a diagnosis for equity upside

The market is expecting GILD to see significant declines in UAFRS-based (Uniform) ROA going forward, to the low end of peer profitability levels, from current best-in-class levels, with slower growth also. The company currently trades at the low end of historical valuations and the low end of peer valuations, highlighting the market’s pessimism.

To get access to all of our newsletter reports, please log into the Valens Research web app. If you don't have an account, you can sign up for the 30-day trial.